Published in Clinical Oncology Week, September 12th, 2005
Study 1: Scientists suggested that chronic lymphocytic leukemic (CLL) cells exhibited apoptotic signaling via TRAIL-R1.
"Clinical trials have been initiated with Apo2L/TRAIL (Genentech) and agonistic mAbs to TRAIL receptors, -R1 and -R2 (Human Genome Sciences). The apoptosis-inducing ability of these mAbs and different TRAIL preparations, in the presence or absence of histone deacetylase inhibitors (HDACi), varied markedly against primary CLL cells and various tumor cell lines, demonstrating an unanticipated preferential apoptotic signaling via either TRAIL-R1...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.